Literature DB >> 23630207

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.

Stéphane Vignot1, Garrett M Frampton, Jean-Charles Soria, Roman Yelensky, Frédéric Commo, Christian Brambilla, Gary Palmer, Denis Moro-Sibilot, Jeffrey S Ross, Maureen T Cronin, Fabrice André, Philip J Stephens, Vladimir Lazar, Vincent A Miller, Elisabeth Brambilla.   

Abstract

PURPOSE: Characterization of the genomic changes that drive an individual patient's disease is critical in management of many cancers. In patients with non-small-cell lung cancer (NSCLC), obtaining tumor samples of sufficient size for genomic profiling on recurrence is often challenging. We undertook this study to compare genomic alterations identified in archived primary tumors from patients with NSCLC with those identified in metachronous or synchronous metastases. PATIENTS AND METHODS: Primary and matched metastatic tumor pairs from 15 patients were analyzed by using a targeted next-generation sequencing assay in a Clinical Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage.
RESULTS: Among 30 tumors, 311 genomic alterations were identified of which 63 were known recurrent (32 in primary tumor, 31 in metastasis) and 248 were nonrecurrent (likely passenger). TP53 mutations were the most frequently observed recurrent alterations (12 patients). Tumors harbored two or more (maximum four) recurrent alterations in 10 patients. Comparative analysis of recurrent alterations between primary tumor and matched metastasis revealed a concordance rate of 94% compared with 63% for likely passenger alterations.
CONCLUSION: This high concordance suggests that for the purposes of genomic profiling, use of archived primary tumor can identify the key recurrent somatic alterations present in matched NSCLC metastases and may provide much of the relevant genomic information required to guide treatment on recurrence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23630207     DOI: 10.1200/JCO.2012.47.7737

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  79 in total

1.  Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.

Authors:  Gaurav Singal; Peter G Miller; Vineeta Agarwala; Gerald Li; Gaurav Kaushik; Daniel Backenroth; Anala Gossai; Garrett M Frampton; Aracelis Z Torres; Erik M Lehnert; David Bourque; Claire O'Connell; Bryan Bowser; Thomas Caron; Ezra Baydur; Kathi Seidl-Rathkopf; Ivan Ivanov; Garrett Alpha-Cobb; Ameet Guria; Jie He; Shannon Frank; Allen C Nunnally; Mark Bailey; Ann Jaskiw; Dana Feuchtbaum; Nathan Nussbaum; Amy P Abernethy; Vincent A Miller
Journal:  JAMA       Date:  2019-04-09       Impact factor: 56.272

2.  Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

Authors:  Li-Hui Tseng; Federico De Marchi; Aparna Pallavajjalla; Erika Rodriguez; Rena Xian; Deborah Belchis; Christopher D Gocke; James R Eshleman; Peter Illei; Ming-Tseh Lin
Journal:  Am J Clin Pathol       Date:  2019-10-07       Impact factor: 2.493

3.  Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Authors:  Benjamin A Weinberg; Kyle Gowen; Thomas K Lee; Sai-Hong Ignatius Ou; Robert Bristow; Lauren Krill; M Isabel Almira-Suarez; Siraj M Ali; Vincent A Miller; Stephen V Liu; Samuel J Klempner
Journal:  Oncologist       Date:  2017-02-13

Review 4.  Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches.

Authors:  Haley J Abel; Eric J Duncavage
Journal:  Cancer Genet       Date:  2013-11-20

Review 5.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 6.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

Review 7.  Management pathways for solitary pulmonary nodules.

Authors:  Masaoki Ito; Yoshihiro Miyata; Morihito Okada
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

8.  What we have known, what we do not know?-clonality of multifocal pulmonary ground-glass opacities.

Authors:  Jun Wang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

9.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

Review 10.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.